---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-22-008523"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:57:59.613670+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx reports Q3 2022 results; cash $16.4M, monthly burn ~$2.3M; new global vet supply deal

## Summary
- Cash at Sep 30: $16.4M; net cash used in operations ~$2.3M/month.
- Raised ~$6.4M net from public offering; secured $1.5M non-dilutive from Namur Invest.
- Post-quarter: signed global supply agreement for Nu.Q Vet Cancer Test with a pet healthcare market leader; launched via Heska in U.S. and soon Europe.
- Appointed DXOCRO for U.S. clinical validation studies of Nu.Q NETs and Cancer tests; pre-submission to FDA anticipated in 2023.
- Started lung cancer biomarker study with Hospices Civils de Lyon (ILYAD) to develop national screening program.

## SEC filing metadata
- accession: 0001477932-22-008523
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/0001477932-22-008523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-22-008523
- JSON: https://secwatch.observer/filing/0001477932-22-008523.json
- Plain text: https://secwatch.observer/filing/0001477932-22-008523.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793222008523/0001477932-22-008523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.